Do You Have Type 2 Diabetes?
The UNC Diabetes Care Center is currently seeking volunteers to participate in a research study of an investigational form of INT131 besylate medication for the treatment of diabetes. Four doses of INT131 besylate will be tested. These 4 doses will be compared against placebo (inactive substance) and pioglitazone (Actos), which is approved by the FDA for the treatment of type 2 diabetes. The length of the study is 28 weeks or approximately 8 months, and visits will take place at the UNC Diabetes Care Center.
Study related benefits at no cost to you include, study medication, related lab testing, ECGs, physical exams, glucose monitoring and compensation for your time.
You may qualify if
* you are 18 years of age or older
* you have type 2 diabetes
* you are taking the oral anti-diabetic medication metformin, a sulfonylurea drug such as Amaryl or Glyburide or a combination of both
Study Protocol INT131-007 IRB Approval Study No 08-0329 Approval Date 3 April 2008 UNC Biomedical IRB Approval by Full Board Review
For more information please call Laura Ely, Clinical Trials Coordinator, UNC Diabetes Care Center
484 0931 ext 268
lely@med.unc.edu
or you may register on our Registry for Potential Research Study Patients at the following link:
http://domis.med.unc.edu/dccregistry
Do You Have Type 2 Diabetes?
The UNC Diabetes Care Center is currently seeking volunteers to participate in a research study of an investigational form of exenatide LAR medication for the treatment of diabetes. Exenatide LAR is a long acting version of exenatide (Byetta). As a study participant you will be receive at least one active study drug, (exenatide LAR), Januvia (sitagliptin) or Actos (pioglitazone) and at least one inactive study drug (oral placebo or placebo LAR). The length of the study is approximately 2 years and visits will take place at the UNC Diabetes Care Center and the Carolina Center for Clinical Trials.
Study-related benefits at no cost to you include, study medication, related lab testing, ECGs, physical exams, glucose monitoring and compensation for your time.
You may qualify if you
are 18 years of age or older
have type 2 diabetes
are taking the oral anti-diabetic medication metformin
Study BCB 106 IRB Approval Study No 07-1929
Approval Date 8 April 2008
UNC Biomedical IRB Approval by Full Board Review
For more information please call
Gail Fuller Clinical Trials Coordinator
UNC Diabetes Care Center
484 0931 ext 274
gpfuller@med.unc.edu
Investigational implantable device
If you have type 2 diabetes and are overweight, you may be eligible to participate in a study of an investigational implantable device. This study, called the TANTALUS II System for the treatment of type 2 diabetes, is investigating where the TANTALUS II System is effective in improving blood sugar control. The study will also evaluate the impact on weight loss and will study other health conditions related to being overweight.
Study participation lasts approximately 3 years and includes an estimated 18 visits. Qualified participants will receive study-related care. Financial compensation is also provided. To qualify you cannot be on insulin, symlin or byetta or take narcotic pain medications on a regular basis.
For more information on the TANTALUS II System study or to schedule an initial screening visit, call April Goley of the Diabetes Care Center of the University of North Carolina-Chapel Hill, at 919-484-0931 ext 270.
This study has been approved by the Institutional Review Board at UNC-CH. IRB#: 08-0119.
Painful Peripheral Neuropathy Study
We are looking for diabetics with painful peripheral neuropathy to
participate in a study of an investigational oral medication in people
with hand, foot, or leg pain caused by diabetes-related nerve damage.
You may be eligible if you
- are at least 18 years old
- have been diagnosed with Type 1 or Type 2 diabetes mellitus with at least 6
months of moderate to severe peripheral pain
- have had peripheral pain that is not being relieved with over-the-counter or
prescription analgesics for at least 3 months
- have had controlled blood glucose for at least 3 months
Study participation lasts approximately 5 months and requires 13 office visits and 1 follow-up phone call. All study-related office visits,
medical evaluations, and study medication will be provided to qualified
study participants at no cost.
For more information, please contact
Erika Hanami, CRC
99 Manning Drive
1042 Burnett-Womack, CB 7209
Chapel Hill, NC 27599-7209
Phone: 919-843-5126
Fax: 919-843-2477
Email: erika_hanami@med.unc.edu
http://www.med.unc.edu/ccct
This study has been approved by the Institutional Review Board at
UNC-CH. IRB#: 07-0682
Heels and Hearts is a student diabetes group sponsored by UNC Campus Health Services. We are interested in community outreach to people with diabetes especially to children. Heels and Hearts teams will be at RTP for the ADA
walk Sept 30 http://www.diabetes.org and the JDRF walk on Oct 28. http://walk.jdrf.org/index.cfm?fuseaction=extranet.personalpage&confirmid=86435031 .
We would especially like to let you know about our DIABETES MENTOR PROGRAM. UNC students and recent graduates have developed a contact program to provide phone support to youth with diabetes. With the parent's approval,
the youth may call one of our mentors. Mentors have been trained in effective listening skills, appropriate boundaries and when to refer an issue to the patient's health care team. Our Campus Health Services diabetes team professionals provide training and support for the mentors. If you would like a contact list of Heels and Hearts diabetes mentors for your clinic, please send email to Margaret Vimmerstedt MD.
Margaret Vimmerstedt MD
mvimm@email.unc.edu
UNC Campus Health Services
CB#7470
Chapel Hill, NC 27517-7470
If you have Type 2 Diabetes, you may be eligible for a National Institute of Health research study seeking new ways to treat Type 2 Diabetes.
The study is called TINSAL-T2D, Targeting INflammation using Salsalate in Type 2 Diabetes. This study looks at the safety and effectiveness of
an investigational medication (similar to aspirin) in the treatment of
Type 2 Diabetes. The study medication has been approved by the U.S.
Food and Drug Administration (FDA) to treat arthritis but it has not
been approved for diabetes.
To be considered for this important diabetes study you must meet the
following criteria:
- Have Type 2 Diabetes
- Be between 18-75 years of age
- Be on a stable dose of oral anti-diabetic medication and your diabetes
is still not well controlled
Participation includes
- 8 visits over 21 weeks
- Physical exam at no cost
- Laboratory testing at no cost
- Participation in cutting edge research for new treatments for Type 2 diabetes
- Compensation for time, effort, and inconvenience of participating
For more information on the TINSAL-T2D study or to schedule an initial
screening visit, call the Diabetes Care Center of the University of
North Carolina-Chapel Hill, Susan S, Braithwaite, M.D., or the Study
Coordinator at 919-966-1253
This study and advertisment was approved by the UNC IRB, study #06-0456
and GCRC #2530 on 1/8/2007.
Connect to the National Diabetes Education Program
|
